#India #AI Innovations #Ahmedabad #Veeda Lifesciences #Mango Sciences

Veeda Lifesciences Announces Strategic Partnership with Mango Sciences

In a significant move towards integrating advanced technologies into clinical research, Veeda Lifesciences, a renowned global contract research organization (CRO), has officially announced its investment in
Mango Sciences, a healthcare-focused AI and data analytics company based in Boston. This collaboration aims to enhance the quality and efficiency of clinical trials through innovative artificial intelligence capabilities.

Enhancing Clinical Trial Processes

The partnership signals a pivotal step for Veeda, which is committed to improving its operational efficiency within its extensive global network. By leveraging Mango Sciences' AI-driven platform, Querent™, Veeda plans to automate patient identification processes with greater precision. This will not only streamline recruitment efforts but also ensure a more diverse and representative selection of participants for clinical studies across Europe and beyond.

Dr. Mahesh Bhalgat, Group CEO and Managing Director of Veeda Clinical Research Limited, stated, "Our collaboration will transform Veeda into an AI-driven organization dedicated to cancer drug development, fulfilling the increasing demand for diversity in clinical trials. This aligns well with the expectations of regulatory bodies and pharmaceutical companies. We will be among the few CROs focusing on oncology with access to proprietary technology."

Commitment to Technology Modernization

Veeda's partnership with Mango Sciences is part of a broader strategy to invest in technological modernization and digital transformation. This investment aims to enhance operational efficiency and quality assurance throughout the clinical research landscape. The integration of Mango's AI technology is expected to improve data management processes and boost the quality standards by ensuring broader representation of non-Caucasian populations in clinical research.

Through advanced data analytics, Veeda anticipates an enhancement in the efficiency of clinical trials, including faster patient allocation, optimized study designs, and improved monitoring—all while reducing costs and shortening timelines.

Dr. Mohit Misra, Founder and CEO of Mango Sciences, emphasized the capabilities of their technology, stating, "We are incorporating Large Language Models (LLMs) and Generative-AI into Querent™ to enhance operational efficiency and improve real-world evidence, ultimately identifying the right drug for the right patient."

Strengthening Competitive Edge in CRO Sector

Veeda has solidified its position as a technology-driven CRO through strategic investments and previous acquisitions, including Health Data Specialists (Heads). This acquisition grants Veeda access to oncology cohorts in India and Europe, alongside exclusive access to suitable patient pools. Such efforts are essential for Veeda's goal of maintaining a competitive edge in the CRO sector while delivering top-notch services to pharmaceutical and biopharmaceutical clients worldwide.

About Veeda Lifesciences

Veeda Lifesciences offers a comprehensive range of services throughout various phases of the drug development value chain. By supporting small to mid-sized biotech and pharmaceutical companies, Veeda covers capabilities ranging from preclinical development to clinical pharmacology and clinical trials in various modalities. For more information, visit Veeda Lifesciences.

About Mango Sciences

Mango Sciences is dedicated to enhancing patient care through advanced data analytics and healthcare solutions. Founded by industry veterans with extensive experience in healthcare, life sciences, and data analysis, Mango Sciences aims to improve patient representation and access to comprehensive healthcare. For further details, explore Mango Sciences.

Conclusion

The partnership between Veeda Lifesciences and Mango Sciences marks a significant advancement in clinical trial methodologies, leveraging AI to foster increased efficiency and diversity in patient recruitment. As this collaboration unfolds, it is positioned to make meaningful contributions to the future of clinical research, particularly in the oncology sector.